SCHEMBL24837458

SCHEMBL24837458

CC(C)Oc1ccc(S(=N)(=O)C(F)(F)F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR4 Q5NUL3 1/20 0.44
▸ PTPN5 P54829 1/20 0.42
▸ ALDH1A3 P47895 1/20 0.42
▸ MMP3 P08254 3/20 0.41
▸ MMP2 P08253 2/20 0.41
▸ MMP9 P14780 2/20 0.41
▸ MMP14 P50281 2/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ MMP1 P03956 1/20 0.40
▸ MMP7 P09237 1/20 0.40
▸ MMP8 P22894 1/20 0.40
▸ MMP13 P45452 1/20 0.40
▸ PARP10 Q53GL7 1/20 0.40
▸ PTPRZ1 P23471 1/20 0.39
▸ CNR2 P34972 1/20 0.39
▸ DHCR7 Q9UBM7 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ GLA P06280 1/20 0.37
▸ PTGS2 P35354 2/20 0.36
▸ CA12 O43570 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24010109 0.80 PKM (0.55) MMP2MMP9KMT2AMMP1MMP8
SCHEMBL24931277 0.78 FFAR4 (0.49) FFAR4ALDH1A3MMP3MMP2MMP9
SCHEMBL22444902 0.77 CXCR2 (0.51) FFAR4PTPN5ALDH1A3MMP3MMP2
SCHEMBL24837401 0.77 LMNA (0.43) PTPN5KMT2ACNR2POLBPTGS2
SCHEMBL930312 0.75 PKM (0.58) FFAR4ALDH1A3MMP3MMP2MMP9
SCHEMBL13364187 0.74 GAA (0.50) MMP2MMP9KMT2AMMP1MMP8
SCHEMBL9034923 0.74 PTGS2 (0.55) FFAR4ALDH1A3MMP3MMP2MMP9
SCHEMBL344199 0.72 FFAR4 (0.50) FFAR4ALDH1A3MMP3MMP2MMP9
SCHEMBL189284 0.72 ALDH1A1 (0.59) FFAR4ALDH1A3PARP10PTGS2CA12
SCHEMBL13588841 0.72 FFAR4 (0.50) FFAR4ALDH1A3MMP3MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2023-10-10 — — US disclosed
US-20230002406-A1 IMINO SULFANONE INHIBITORS OF ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2023-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 ENPP1, ENPP3, SMPD1 FFAR4 4607/4885PTPN5 843/4885ALDH1A3 1906/4885
US-20230002406-A1 IMINO SULFANONE INHIBITORS OF ENPP1 ENPP1, ENPP3, SMPD1 FFAR4 4607/4885PTPN5 843/4885ALDH1A3 1906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback